Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification

The authors evaluate emerging strategies for hepatocellular carcinoma (HCC) surveillance, specifically abbreviated magnetic resonance imaging (aMRI) and blood-based biomarker panels, to address the limitations of current ultrasound and AFP methods. They propose that future clinical implementation of these tests should focus on benefit stratification, assessing not only the risk of developing HCC but also the potential clinical outcomes from earlier detection and treatment. The paper emphasizes the need for individualized frameworks to determine which patients would most benefit from enhanced surveillance.